Gintsburg: Oncovaccines for 20 melanoma patients will be prepared…
Gintsburg: Oncovaccines for 20 melanoma patients will be prepared within 1.5 to 2 months.
Consensus
- Personalized oncovaccines for melanoma will be ready within 1.5 to 2 months, at most 3.
- The first patient received the vaccine on April 1.
- The patient is a 60-year-old man from Kursк Oblast with skin cancer.
- Approximately 20 patients are currently in line to receive the vaccine.
- Genetic information from the first 10 patients has been processed and synthesis has been completed.
- The vaccine is being developed at the National Research Center for Epidemiology and Microbiology (NICEM) named after N.F. Gamaleya.
- Alexander Gintsburg, the scientific director of NICEM, is the main source of information in all reports.
Points of divergence
- The vaccine is intended for primary melanoma patients with stage IIIB-III D and those with local recurrence after surgery. — kommersant
- The first patient received the vaccine on April 1, and the results of effectiveness will appear in several months. — vesti
- In May, it was reported that a patient received the peptide vaccine 'Onkopept' for colorectal cancer, which had undergone 6 administrations and showed good tolerance and immune response. — m24
- The Vector Center has started developing mRNA vaccines against HIV (AIDS), monkeypox, and tick-borne encephalitis. — m24
Coverage (3 sources)
- Ginzburg reported on timelines for receiving oncovaccine for melanoma patients — Коммерсантъ
- The first 20 personal melanoma oncovaccines will be ready in the coming months — Вести
- Ginzburg: Oncovaccines for 20 patients with melanoma will be prepared within 1.5–2 months — Москва 24
Key entities
- Alexander Ginzburg
- TASS
- Moscow
- Kursk Oblast
- N. F. Gamaleya National Research Center
- National Research Center for Epidemiology and Microbiology (NRECM) named after N. F. Gamalei
- Yulia Ivanco Personal
- NICTEM